FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
8.50
-0.08 (-0.99%)
Dec 24, 2025, 4:00 PM EST - Market closed
FibroGen Revenue
FibroGen had revenue of $1.08M in the quarter ending September 30, 2025, with 774.80% growth. This brings the company's revenue in the last twelve months to $-118.09M. In the year 2024, FibroGen had annual revenue of $29.62M, down -36.71%.
Revenue (ttm)
$-118.09M
Revenue Growth
-36.71%
P/S Ratio
4.18
Revenue / Employee
$36,880
Employees
225
Market Cap
34.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.62M | -17.18M | -36.71% |
| Dec 31, 2023 | 46.80M | -93.93M | -66.74% |
| Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
| Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
| Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
| Dec 31, 2019 | 256.58M | 43.62M | 20.48% |
| Dec 31, 2018 | 212.96M | 81.96M | 62.57% |
| Dec 31, 2017 | 131.00M | -52.19M | -28.49% |
| Dec 31, 2016 | 183.19M | 2.36M | 1.31% |
| Dec 31, 2015 | 180.83M | 43.23M | 31.41% |
| Dec 31, 2014 | 137.60M | 35.43M | 34.68% |
| Dec 31, 2013 | 102.17M | 36.24M | 54.96% |
| Dec 31, 2012 | 65.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FGEN News
- 6 weeks ago - FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - FibroGen to Report Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 4 months ago - FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - GlobeNewsWire
- 4 months ago - FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - FibroGen to Report Second Quarter 2025 Financial Results - GlobeNewsWire